To study the effects of RNAi-mediated inhibition in β-catenin-mutated HCC, we utilized a novel siRNA that targets the CTNNB1 gene, with both mouse and human specificity, encapsulated in a lipid nanoparticle (referred hereafter as LNP-CTNNB1). Here, CTNNB1 is linked to hepatocellular carcinoma.